We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (1)
- In development advice (0)
Set out priority areas for quality improvement in health and social care.
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject.
Guidance by programme
Review the evidence across broad health and social care topics.
Reviews the clinical and cost-effectiveness of new treatments.
Review clinical and cost-effectiveness of specialised treatments.
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Advice by programme
Products being developed or updated
Comment on guidance in development
Current guidance in consultation
News on this topic
NICE’s new guideline is the first to offer comprehensive information on neurological conditions to help non-specialist healthcare professionals to identify people who should be referred for specialist assessment and care.
NICE has published draft guidance which confirms its earlier decision not to recommend cerliponase alfa (also called Brineura and made by Biomarin) for children with Batten disease – a very rare inherited condition affecting between 1 and 6 babies each year in the UK.
Putting guidance into practice
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 3 shared learning examples for this topic: